Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters

To support the development of new therapies for children, Pharmetheus commonly applies graphical analysis and model predictions comparing adult and pediatric data. In a recently published article, Daniel Röshammar and collaborators showed a similar relationship between dabigatran exposure and the effects on coagulation laboratory parameters in adults and children. The work supported age- and weight-adjusted dosing of dabigatran as appropriate in children with venous thromboembolism.


Find the publication here.

Pharmetheus affiliates: Daniel Röshammar
List of Daniel’s publications
Pharmetheus’ publications

Mitchell LG, Röshammar D, Huang F, Albisetti M, Brandão LR, Bomgaars L, Chalmers E, Halton J, Luciani M, Joseph D, Tartakovsky I. Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. Thrombosis and Haemostasis. 2022 Jul 31. Photo of Daniel Röshammar. Pharmetheus Logo